SARS-CoV-2 Variants of Concern Hijack IFITM2 for Efficient Replication in Human Lung Cells.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
08 06 2022
Historique:
pubmed: 12 5 2022
medline: 11 6 2022
entrez: 11 5 2022
Statut: ppublish

Résumé

It has recently been shown that an early SARS-CoV-2 isolate (NL-02-2020) hijacks interferon-induced transmembrane proteins (IFITMs) for efficient replication in human lung cells, cardiomyocytes, and gut organoids. To date, several "variants of concern" (VOCs) showing increased infectivity and resistance to neutralization have emerged and globally replaced the early viral strains. Here, we determined whether the five current SARS-CoV-2 VOCs (Alpha, Beta, Gamma, Delta, and Omicron) maintained the dependency on IFITM proteins for efficient replication. We found that depletion of IFITM2 strongly reduces viral RNA production by all VOCs in the human epithelial lung cancer cell line Calu-3. Silencing of IFITM1 had modest effects, while knockdown of IFITM3 resulted in an intermediate phenotype. Strikingly, depletion of IFITM2 generally reduced infectious virus production by more than 4 orders of magnitude. In addition, an antibody directed against the N terminus of IFITM2 inhibited SARS-CoV-2 VOC replication in induced pluripotent stem cell (iPSC)-derived alveolar epithelial type II cells, thought to represent major viral target cells in the lung. In conclusion, endogenously expressed IFITM proteins (especially IFITM2) are critical cofactors for efficient replication of genuine SARS-CoV-2 VOCs, including the currently dominant Omicron variant.

Identifiants

pubmed: 35543509
doi: 10.1128/jvi.00594-22
pmc: PMC9175628
doi:

Substances chimiques

IFITM2 protein, human 0
IFITM3 protein, human 0
Membrane Proteins 0
RNA-Binding Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0059422

Subventions

Organisme : NCATS NIH HHS
ID : U01 TR001810
Pays : United States

Références

Appl Microbiol Biotechnol. 2021 Dec;105(24):9035-9045
pubmed: 34755213
ACS Nano. 2021 May 25;15(5):8155-8170
pubmed: 33656312
Cell Stem Cell. 2017 Oct 5;21(4):472-488.e10
pubmed: 28965766
EMBO J. 2021 Aug 16;40(16):e107821
pubmed: 34159616
Nat Microbiol. 2021 Oct;6(10):1219-1232
pubmed: 34471255
Nat Protoc. 2019 Dec;14(12):3303-3332
pubmed: 31732721
Nat Med. 2022 Mar;28(3):490-495
pubmed: 35046573
Virus Res. 2022 Jul 2;315:198765
pubmed: 35367284
Cell Mol Gastroenterol Hepatol. 2021;11(4):935-948
pubmed: 33186749
Dis Model Mech. 2021 Jun 1;14(6):
pubmed: 34219165
Lancet. 2021 Jun 26;397(10293):2461-2462
pubmed: 34139198
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
PNAS Nexus. 2022 Sep 01;1(5):pgac180
pubmed: 36712320
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Virol. 2022 Mar 23;96(6):e0207721
pubmed: 35225672
Nat Commun. 2021 Jul 28;12(1):4584
pubmed: 34321474
J Med Virol. 2022 Apr;94(4):1641-1649
pubmed: 34914115
Euro Surveill. 2021 Mar;26(10):
pubmed: 33706862
Cell Host Microbe. 2014 Dec 10;16(6):736-47
pubmed: 25464829
J Med Virol. 2022 Mar;94(3):821-822
pubmed: 34596249
mBio. 2020 Oct 16;11(5):
pubmed: 33067384
Annu Rev Virol. 2014 Nov 1;1:261-283
pubmed: 25599080
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
Lancet. 2020 Jun 6;395(10239):1757-1758
pubmed: 32446324
Cell Stem Cell. 2020 Dec 3;27(6):962-973.e7
pubmed: 32979316
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Cell. 2020 May 28;181(5):1016-1035.e19
pubmed: 32413319
Front Microbiol. 2019 Jan 08;9:3228
pubmed: 30687247
Retrovirology. 2017 Nov 21;14(1):53
pubmed: 29162141
Sci Rep. 2017 Dec 21;7(1):17972
pubmed: 29269892
Emerg Microbes Infect. 2022 Dec;11(1):277-283
pubmed: 34951565
Microorganisms. 2021 Jul 20;9(7):
pubmed: 34361977
J Biol Chem. 2013 Nov 8;288(45):32184-32193
pubmed: 24067232
EMBO J. 2021 Feb 1;40(3):e106501
pubmed: 33270927
Science. 2021 May 21;372(6544):815-821
pubmed: 33853970
J Microbiol. 2021 Sep;59(9):807-818
pubmed: 34449057
Proc Natl Acad Sci U S A. 2014 May 6;111(18):6756-61
pubmed: 24753610
Cell Rep. 2022 May 17;39(7):110829
pubmed: 35550680
Cell. 2021 Sep 30;184(20):5189-5200.e7
pubmed: 34537136
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
J Virol. 2022 Dec 14;96(23):e0125022
pubmed: 36350154
Front Immunol. 2022 Jan 24;12:830527
pubmed: 35140714
PLoS Pathog. 2013 Jan;9(1):e1003124
pubmed: 23358889
EMBO Rep. 2023 Apr 5;24(4):e56660
pubmed: 36880581
Viruses. 2014 Sep 26;6(9):3683-98
pubmed: 25256397
Cell. 2020 Oct 29;183(3):739-751.e8
pubmed: 32991842
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Viruses. 2022 Mar 30;14(4):
pubmed: 35458456
Genome Biol. 2019 Jan 8;20(1):8
pubmed: 30621750
Nature. 2021 Jul;595(7865):107-113
pubmed: 33915569
Nature. 2021 Nov;599(7883):114-119
pubmed: 34488225
Genome Med. 2022 Jan 27;14(1):10
pubmed: 35086559
Nat Rev Immunol. 2013 Jan;13(1):46-57
pubmed: 23237964
Nat Med. 2020 May;26(5):681-687
pubmed: 32327758
EMBO J. 2020 Dec 1;39(23):e106267
pubmed: 33051876

Auteurs

Rayhane Nchioua (R)

Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.

Annika Schundner (A)

Institute of General Physiology, Ulm University Medical Center, Ulm, Germany.

Dorota Kmiec (D)

Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.

Caterina Prelli Bozzo (C)

Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.

Fabian Zech (F)

Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.

Lennart Koepke (L)

Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.

Alexander Graf (A)

Laboratory for Functional Genome Analysis, Gene Center, LMU München, Munich, Germany.

Stefan Krebs (S)

Laboratory for Functional Genome Analysis, Gene Center, LMU München, Munich, Germany.

Helmut Blum (H)

Laboratory for Functional Genome Analysis, Gene Center, LMU München, Munich, Germany.

Manfred Frick (M)

Institute of General Physiology, Ulm University Medical Center, Ulm, Germany.

Konstantin M J Sparrer (KMJ)

Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.

Frank Kirchhoff (F)

Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH